Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1973 1
1974 1
1975 2
1977 2
1979 1
1980 2
1981 1
1982 4
1983 2
1984 2
1985 7
1986 7
1987 9
1988 15
1989 16
1990 6
1991 3
1992 6
1993 4
1994 10
1995 8
1996 8
1997 4
1998 4
1999 5
2000 1
2001 7
2002 6
2003 4
2004 5
2005 4
2006 7
2007 4
2008 2
2009 4
2010 4
2011 8
2012 3
2013 5
2014 3
2015 2
2016 3
2017 3
2019 4
2020 4
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

208 results
Results by year
Filters applied: . Clear all
Page 1
Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention.
Nasi A, McArdle S, Gaudernack G, Westman G, Melief C, Rockberg J, Arens R, Kouretas D, Sjölin J, Mangsbo S. Nasi A, et al. Among authors: gaudernack g. Toxicol Rep. 2020 Jun 18;7:768-771. doi: 10.1016/j.toxrep.2020.06.003. eCollection 2020. Toxicol Rep. 2020. PMID: 32632359 Free PMC article.
NK cells specifically TCR-dressed to kill cancer cells.
Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR, Fåne A, Gaudernack G, Kvalheim G, Myklebust JH, Inderberg EM, Wälchli S. Mensali N, et al. Among authors: gaudernack g. EBioMedicine. 2019 Feb;40:106-117. doi: 10.1016/j.ebiom.2019.01.031. Epub 2019 Jan 18. EBioMedicine. 2019. PMID: 30665853 Free PMC article.
Therapeutic vaccines for cancer: an overview of clinical trials.
Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I, Mellstedt H. Melero I, et al. Among authors: gaudernack g. Nat Rev Clin Oncol. 2014 Sep;11(9):509-24. doi: 10.1038/nrclinonc.2014.111. Epub 2014 Jul 8. Nat Rev Clin Oncol. 2014. PMID: 25001465 Review.
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.
Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM. Dillard P, et al. Among authors: gaudernack g. Mol Ther. 2021 Mar 3;29(3):1199-1213. doi: 10.1016/j.ymthe.2020.11.019. Epub 2020 Nov 17. Mol Ther. 2021. PMID: 33212301 Free article.
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity.
Mensali N, Grenov A, Pati NB, Dillard P, Myhre MR, Gaudernack G, Kvalheim G, Inderberg EM, Bakke O, Wälchli S. Mensali N, et al. Among authors: gaudernack g. Oncoimmunology. 2019 Jan 11;8(3):1558663. doi: 10.1080/2162402X.2018.1558663. eCollection 2019. Oncoimmunology. 2019. PMID: 30723591 Free PMC article.
A TCR-based Chimeric Antigen Receptor.
Walseng E, Köksal H, Sektioglu IM, Fåne A, Skorstad G, Kvalheim G, Gaudernack G, Inderberg EM, Wälchli S. Walseng E, et al. Among authors: gaudernack g. Sci Rep. 2017 Sep 6;7(1):10713. doi: 10.1038/s41598-017-11126-y. Sci Rep. 2017. PMID: 28878363 Free PMC article.
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
Brunsvig PF, Guren TK, Nyakas M, Steinfeldt-Reisse CH, Rasch W, Kyte JA, Juul HV, Aamdal S, Gaudernack G, Inderberg EM. Brunsvig PF, et al. Among authors: gaudernack g. Front Immunol. 2020 Nov 26;11:572172. doi: 10.3389/fimmu.2020.572172. eCollection 2020. Front Immunol. 2020. PMID: 33324397 Free PMC article.
208 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page